155 related articles for article (PubMed ID: 1609034)
1. Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements after neuroleptic dose decrease.
Newcomer JW; Riney SJ; Vinogradov S; Csernansky JG
Psychopharmacol Bull; 1992; 28(1):101-7. PubMed ID: 1609034
[TBL] [Abstract][Full Text] [Related]
2. Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements during maintenance haloperidol treatment in male patients with schizophrenia.
Newcomer JW; Riney SJ; Vinogradov S; Csernansky JG
Psychiatry Res; 1992 Mar; 41(3):191-202. PubMed ID: 1594706
[TBL] [Abstract][Full Text] [Related]
3. Plasma homovanillic acid levels and therapeutic outcome in schizophrenics: comparisons of neuroleptic-naive first-episode patients and patients with disease exacerbation due to neuroleptic discontinuance.
Akiyama K; Tsuchida K; Kanzaki A; Ujike H; Hamamura T; Kondo K; Mutoh S; Miyanagi K; Kuroda S; Otsuki S
Biol Psychiatry; 1995 Nov; 38(10):639-48. PubMed ID: 8555375
[TBL] [Abstract][Full Text] [Related]
4. Negative symptoms in nondeficit syndrome respond to neuroleptic treatment with changes in plasma homovanillic acid concentrations.
Suzuki E; Kanba S; Koshikawa H; Nibuya M; Yagi G; Asai M
J Psychiatry Neurosci; 1996 May; 21(3):167-71. PubMed ID: 8935328
[TBL] [Abstract][Full Text] [Related]
5. Neurochemical studies on tardive dyskinesia. I. Urinary homovanillic acid and plasma prolactin.
Tripodianakis J; Markianos M; Garelis E
Biol Psychiatry; 1983 Mar; 18(3):337-45. PubMed ID: 6132625
[TBL] [Abstract][Full Text] [Related]
6. Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients.
Baeza I; Castro-Fornieles J; Deulofeu R; de la Serna E; Goti J; Salvà J; Bernardo M
Psychiatry Res; 2009 Jul; 168(2):110-8. PubMed ID: 19501918
[TBL] [Abstract][Full Text] [Related]
7. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W
J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702
[TBL] [Abstract][Full Text] [Related]
8. Relationship of symptomatology, gender, and antipsychotic drug treatment with plasma homovanillic acid in schizophrenia.
Zhang ZJ; Reynolds GP; Ramchand C; Peet M; Shah S
Acta Pharmacol Sin; 2001 Jan; 22(1):76-80. PubMed ID: 11730567
[TBL] [Abstract][Full Text] [Related]
9. Plasma homovanillic acid levels in schizophrenic patients: correlation with negative symptoms.
Dávila R; Zumárraga M; Basterreche N; Arrúe A; Anguiano JB
Psychiatry Res; 2007 May; 151(1-2):163-8. PubMed ID: 17434602
[TBL] [Abstract][Full Text] [Related]
10. Plasma prolactin and plasma homovanillic acid: predictors of clinical response in schizophrenia.
Davila R; Gonzalez MA; Zumarraga M; Andia I; Guimon J; Silva RR; Friedhoff AJ
Biol Psychiatry; 1995 Aug; 38(4):267-9. PubMed ID: 8547450
[No Abstract] [Full Text] [Related]
11. Tardive dyskinesia and plasma homovanillic acid.
Moore DC; Glazer WM; Bowers MB; Heninger GR
Biol Psychiatry; 1983 Dec; 18(12):1393-402. PubMed ID: 6140961
[TBL] [Abstract][Full Text] [Related]
12. Plasma HVA in psychiatric patients: longitudinal studies.
Javaid JI; Sharma RP; Janicak PG; Davis JM
Psychopharmacol Bull; 1990; 26(3):361-5. PubMed ID: 2274637
[TBL] [Abstract][Full Text] [Related]
13. Changes in symptoms and plasma homovanillic acid with amantadine hydrochloride in chronic schizophrenia.
Yamada K; Kanba S; Ohnishi K; Ashikari I; Yagi G; Asai M
Biol Psychiatry; 1997 May; 41(10):1062-4. PubMed ID: 9129786
[No Abstract] [Full Text] [Related]
14. Plasma HVA, tardive dyskinesia and psychotic symptoms in long-term drug-free inpatients with schizophrenia.
Muscettola G; Barbato G; de Bartolomeis A; Monteleone P; Pickar D
Psychiatry Res; 1990 Sep; 33(3):259-67. PubMed ID: 2243901
[TBL] [Abstract][Full Text] [Related]
15. Molindone and haloperidol in tardive dyskinesia.
Glazer WM; Hafez HM; Benarroche CL
J Clin Psychiatry; 1985 Aug; 46(8 Pt 2):4-7. PubMed ID: 2862139
[TBL] [Abstract][Full Text] [Related]
16. Prolactin response in tardive dyskinesia.
Wolf ME; Bowie L; Keener S; Mosnaim AD
Biol Psychiatry; 1982 Apr; 17(4):485-90. PubMed ID: 7082714
[No Abstract] [Full Text] [Related]
17. Minimal effective dose and relapse--double-blind trial: haloperidol decanoate vs. placebo.
Eklund K; Forsman A
Clin Neuropharmacol; 1991; 14 Suppl 2():S7-12; discussion S12-5. PubMed ID: 1684310
[TBL] [Abstract][Full Text] [Related]
18. Plasma catecholamine metabolites and early response to haloperidol.
Bowers MB; Swigar ME; Jatlow PI; Goicoechea N
J Clin Psychiatry; 1984 Jun; 45(6):248-51. PubMed ID: 6725216
[TBL] [Abstract][Full Text] [Related]
19. Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia.
Lieberman JA; Alvir J; Geisler S; Ramos-Lorenzi J; Woerner M; Novacenko H; Cooper T; Kane JM
Neuropsychopharmacology; 1994 Oct; 11(2):107-18. PubMed ID: 7840862
[TBL] [Abstract][Full Text] [Related]
20. The effect of neuroleptic discontinuation on psychopathology, involuntary movements, and biochemical measures in patients with persistent tardive dyskinesia.
Glazer WM; Bowers MB; Charney DS; Heninger GR
Biol Psychiatry; 1989 Jul; 26(3):224-33. PubMed ID: 2568132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
